Other biological mechanisms may, in fact, be responsible for TKI sensitivity in EGFR wild type NSCLC patients, such as EGFR expression or phosphorylation, EGFR amplification, EGFR-ligand expression or the involvement of other biomarkers that play a role in the EGFR pathway [9]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.